Comments Prepared for the CMS Listening Session Regarding the National Coverage Determination Analysis for Aducanumab for Treatment of Alzheimer’s Disease

View as PDF

In comments prepared for the Centers for Medicare and Medicaid Services (CMS) listening session regarding the National Coverage Determination analysis for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease, Public Citizen urged CMS to issue a National Coverage Determination that excludes aducanumab from coverage under the Medicare program because there is a lack of scientific evidence that aducanumab provides any meaningful clinical benefit in terms of cognitive function outcomes in Alzheimer’s disease patients and the drug thus is not reasonable and necessary for treatment of such patients.

See Public Citizen’s other work on aducanumab.